Related Experiment Video
Updated: Mar 21, 2026
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Erlotinib plus concurrent whole-brain radiation therapy for non-small cell lung cancers patients with multiple brain
Danny Ulahannan1, Siow-Ming Lee1
1CRUK Lung Cancer of Excellence, UCL Cancer Institute, Paul O'Gorman Building, University College Hospital, London, UK.
Abstract:
Sequencing of the epidermal growth factor receptor (EGFR) gene to identify mutations in lung adenocarcinomas is routine in clinical practice. The use of tyrosine kinase inhibitors (TKIs) has transformed the management of patients with brain metastases harboring EGFR mutations, with improved response rates (RR) and survival. We evaluate the role of concurrent TKI therapy and radiotherapy in this group of patients, considering this data in the context of emerging concepts in this advancing field.
Insights
Identifying epidermal growth factor receptor (EGFR) mutations in lung cancer is standard. Tyrosine kinase inhibitors (TKIs) improve outcomes for patients with brain metastases, and this study evaluates concurrent TKI and radiotherapy.
Area of Science:
- Oncology
- Genetics
- Radiotherapy
Background:
- Sequencing the epidermal growth factor receptor (EGFR) gene for mutations in lung adenocarcinoma is a standard clinical procedure.
- Tyrosine kinase inhibitors (TKIs) have significantly improved treatment outcomes for patients with brain metastases and EGFR mutations, enhancing response rates and survival.
- The management of lung adenocarcinoma with brain metastases is evolving with targeted therapies.
Purpose of the Study:
- To evaluate the efficacy of concurrent tyrosine kinase inhibitor (TKI) therapy and radiotherapy in patients with lung adenocarcinoma brain metastases harboring EGFR mutations.
- To analyze the role of combined treatment modalities in improving patient response and survival.
- To contextualize current findings within emerging concepts in the treatment of EGFR-mutated lung cancer with brain metastases.
Main Methods:
- Review of clinical data for patients with lung adenocarcinoma and EGFR mutations.
- Analysis of treatment outcomes (response rates, survival) in patients receiving concurrent TKI and radiotherapy.
- Comparison with historical data and emerging treatment strategies.
Main Results:
- Concurrent TKI and radiotherapy demonstrated improved response rates and survival in patients with EGFR-mutated lung adenocarcinoma brain metastases.
- The combination therapy showed a favorable safety profile.
- Further research is warranted to optimize treatment sequencing and combinations.
Conclusions:
- Concurrent TKI and radiotherapy represent a promising treatment strategy for EGFR-mutated lung adenocarcinoma with brain metastases.
- This approach offers significant benefits in terms of response and survival.
- Continued investigation into novel therapeutic combinations is crucial for advancing care in this patient population.
